Provided by Tiger Trade Technology Pte. Ltd.

Rigel Pharmaceuticals

45.11
-0.7800-1.70%
Post-market: 45.110.00000.00%19:58 EDT
Volume:542.01K
Turnover:24.54M
Market Cap:842.65M
PE:2.74
High:46.21
Open:45.63
Low:44.51
Close:45.89
52wk High:52.24
52wk Low:24.95
Shares:18.68M
Float Shares:14.85M
Volume Ratio:1.34
T/O Rate:3.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):16.45
EPS(LYR):19.48
ROE:126.90%
ROA:14.95%
PB:1.98
PE(LYR):2.32

Loading ...

Piper Sandler Sticks to Their Hold Rating for Rigel (RIGL)

TIPRANKS
·
May 13

Rigel Pharmaceuticals price target raised to $81 from $69 at Citi

TIPRANKS
·
May 13

Pfizer PROTAC Licensing Deal With Rigel Adds Royalties To Valuation Story

Simply Wall St.
·
May 13

H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’

TIPRANKS
·
May 13

BUZZ-U.S. STOCKS ON THE MOVE-Tyler Technologies, Autodesk, Illumina

Reuters
·
May 13

Rigel Pharma Shares up 13.4% on Licensing Deal for Pfizer-Arvinas Breast Cancer Drug

THOMSON REUTERS
·
May 12

BUZZ-U.S. STOCKS ON THE MOVE-Under Armour, C3 AI, Rigel Pharma

Reuters
·
May 12

Statutory Earnings May Not Be The Best Way To Understand Rigel Pharmaceuticals' (NASDAQ:RIGL) True Position

Simply Wall St.
·
May 12

Arvinas Grants Rigel Global Rights to VEPPANU Therapy

TIPRANKS
·
May 12

Arvinas, Pfizer Tap Rigel Pharmaceuticals to Bring Veppanu to Market

Dow Jones
·
May 12

Rigel licenses breast cancer drug VEPPANU from Arvinas, Pfizer for USD 70 million

Reuters
·
May 12

BRIEF-Rigel Enters Exclusive Global Licensing Agreement For Veppanu

Reuters
·
May 12

Rigel Enters Exclusive Global Licensing Agreement for Veppanu™ (Vepdegestrant), an Oral Protac, for the Treatment of 2L+ Er+/Her2-, Esr1m Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
May 12

Rigel Pharmaceuticals Inc - to Contribute up to $40 Mln for Development Over Next Four Years

THOMSON REUTERS
·
May 12

Arvinas and Pfizer Enter Into a Transaction With Rigel Pharmaceuticals for the Exclusive Global Rights of Veppanu (Vepdegestrant)

THOMSON REUTERS
·
May 12

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

GlobeNewswire
·
May 12

Knight Therapeutics wins ANVISA approval for Tavalisse in Brazil for chronic ITP

Reuters
·
May 08

Rigel Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
May 08

Rigel Pharmaceuticals publishes corporate presentation outlining commercial growth strategy and pipeline plans

Reuters
·
May 06

Rigel Pharmaceuticals reports Q1 EPS 44c, consensus 87c

TIPRANKS
·
May 06